Effect of Premature Luteinization on the Oocyte Quality in Oocyte Donation Program.

This study has been completed.
Sponsor:
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA
ClinicalTrials.gov Identifier:
NCT00455949
First received: April 3, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

Analyze the possible effect of the progesterone levels of the hCG administration on the oocyte embryo quality. The primary endpoint of this study is the pregnancy rate.


Condition
Premature Luteinization

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal

Further study details as provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:

  Eligibility

Ages Eligible for Study:   18 Years to 34 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Oocyte donors; age range: 18 - 34; BMI: 18 - 29; long protocol.

Exclusion Criteria:

  • PCO syndrome;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00455949

Locations
Spain
Instituto Valenciano de la Infertilidad
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
Investigators
Principal Investigator: Marco Melo, MD Instituto Valenciano de Infertilidad
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00455949     History of Changes
Other Study ID Numbers: VLC-MM-0106-307-14
Study First Received: April 3, 2007
Last Updated: April 3, 2007
Health Authority: Spain: Ministry of Health

ClinicalTrials.gov processed this record on October 16, 2014